ProCE Banner Series

Advances in CDK4/6 Inhibition in EBC: Expert Guidance and Case Challenges for the Multidisciplinary Team

Join us in person or virtually for this live 1-hour workshop series on how the community care team can integrate CDK4/6 inhibitors into adjuvant treatment of early-stage breast cancer. Get up to date on identifying eligible patients, supporting adherence, and managing toxicities.

To Register: Please click the green “Learn More” button below. On the next page, select “Register for Virtual Event.” Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This program is intended for oncologists, surgeons/surgical oncologists, pathologists, radiologists, pharmacists, nurse practitioners, physician associates, oncology nurses, and other healthcare professionals on the multidisciplinary team who care for patients with breast cancer.

All Events

Upcoming Events

April

25

2024

Advances in CDK4/6 Inhibition in EBC: Expert Guidance and Case Challenges for the Multidisciplinary Team [Open Registration]

3:00 PM - 4:00 PM Central Time (CT)

Virtual

CCO Simulcasts | Host Group LA, Baton Rouge, Louisiana

May

02

2024

Advances in CDK4/6 Inhibition in EBC: Expert Guidance and Case Challenges for the Multidisciplinary Team [Open Registration]

6:00 PM - 7:00 PM Central Time (CT)

Virtual

May

03

2024

Advances in CDK4/6 Inhibition in EBC: Expert Guidance and Case Challenges for the Multidisciplinary Team [Open Registration]

11:30 AM - 12:30 PM Eastern Time (ET)

Virtual

CCO Simulcasts | Host Group MD, Baltimore, Maryland

Past Events

January

30

2024

Advances in CDK4/6 Inhibition in EBC: Expert Guidance and Case Challenges for the Multidisciplinary Team

6:00 PM - 7:00 PM Eastern Time (ET)

In-person

Private Event, New Bern, North Carolina

March

06

2024

Advances in CDK4/6 Inhibition in EBC: Expert Guidance and Case Challenges for the Multidisciplinary Team [Open Registration]

3:00 PM - 4:00 PM Eastern Time (ET)

Virtual

CCO Simulcasts | Host Group KY, Lexington, Kentucky

Faculty

ProCE Banner Faculty
Tanya Gupta, MD

Clinical Assistant Professor
Breast Oncology
Stanford Healthcare
Palo Alto, California

ProCE Banner Faculty
Laura A. Huppert, MD

Assistant Professor of Medicine
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California

ProCE Banner Faculty
Reshma Mahtani, DO

Chief of Breast Medical Oncology
Medical Oncology
Miami Cancer Institute
Miami, Florida

ProCE Banner Faculty
Jane Lowe Meisel, MD

Associate Professor of Hematology and Medical Oncology
Associate Vice Chair of Faculty Development and Promotions
Winship Cancer Institute at Emory University
Atlanta, Georgia

ProCE Banner Faculty
Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Texas Oncology
Sarah Cannon Research Institute
Dallas, Texas

ProCE Banner Faculty
Ruta D. Rao, MD

Professor of Medicine
Medical Director, Rush University Cancer Center
Rush University Medical Center
Chicago, Illinois

ProCE Banner Faculty
Cesar A. Santa-Maria, MD, MSCI

Associate Professor of Oncology
Breast and Gynecological Malignancies Group
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

ProCE Banner Faculty
Sara M. Tolaney, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center for Women’s Cancers
Director
Clinical Trials, Breast Oncology
Director
Breast Immunotherapy Clinical Research
Dana-Farber Cancer Institute
Boston, Massachusetts

ProCE Banner Faculty
Kelly E. Westbrook, MD

Assistant Professor, Department of Medicine
Duke University School of Medicine
Division of Oncology, Breast Cancer Program 
Durham, North Carolina

Topics

  • Integrating Adjuvant CDK4/6 Therapy for Appropriate Patients With HR-Positive/HER2-Negative EBC in Your Practice
  • Strategies for Promoting Adherence and Persistence to Oral Therapy in Your Practice
  • Considerations for the Multidisciplinary Team

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, confidence, and competence of learners in applying current data on the use of CDK4/6 inhibitors as part of their care of patients with early-stage breast cancer.

Target Audience
This program is intended for oncologists, surgeons/surgical oncologists, pathologists, radiologists, pharmacists, nurse practitioners, physician associates, oncology nurses, and other healthcare professionals on the multidisciplinary team who care for patients with breast cancer.

Learning Objectives
At the conclusion of this activity, learners should be better able to:

  • Identify patients who may benefit from the addition of CDK4/6 inhibitor therapy to endocrine therapy in the adjuvant setting

  • Plan evidence-based personalized treatment strategies for HR-positive/HER2-negative early breast cancer, fostering collaborative discussions and workflows among the oncology multidisciplinary team

  • Develop strategies that promote optimal adherence and persistence to prescribed oral CDK4/6 inhibitors in patients with early-stage breast cancer

  • Manage adverse events associated with oral targeted therapy in the adjuvant setting for patients with HR-positive/HER2-negative breast cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-24-028-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.